Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

被引：1

作者：

Delimpasi, Sosana ^{[1
,2
]}

Dimopoulos, Meletios A. ^{[3
]}

Straub, Jan ^{[4
]}

Symeonidis, Argiris ^{[5
]}

Hajek, Roman ^{[6
,7
]}

Touzeau, Cyrille ^{[8
]}

Bhanderi, Viralkumar K. ^{[9
]}

Berdeja, Jesus ^{[10
]}

Pavlicek, Petr ^{[11
]}

Matous, Jeffrey, V ^{[12
,13
]}

Robak, Pawel J. ^{[14
,15
]}

Suryanarayan, Kaveri ^{[16
]}

Villareal, Miguel ^{[16
]}

Cherepanov, Dasha ^{[1
,2
,3
]}

Srimani, Jaydeep K. ^{[16
]}

Yao, Huilan ^{[16
]}

Labotka, Richard ^{[16
]}

Orlowski, Robert Z. ^{[17
,18
]}

机构：

[1] Gen Hosp Evangelismos, Dept Hematol, Athens, Greece

[2] Gen Hosp Evangelismos, Bone Marrow Transplantat Unit, Athens, Greece

[3] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Hematol & Med Oncol, Athens, Greece

[4] Univ Hosp, Dept Internal Med Hematol, Prague, Czech Republic

[5] Univ Gen Hosp Patras, Dept Hematol, Patras, Greece

[6] Univ Hosp Ostrava, Ostrava, Czech Republic

[7] Univ Ostrava, Fac Med, Ostrava, Czech Republic

[8] Univ Hosp Hotel Dieu, Nantes, France

[9] Tallahassee Canc Ctr, Florida Canc Specialists, Tallahassee, FL USA

[10] Sarah Cannon Res Inst, Nashville, TN USA

[11] Univ Hosp Kralovske Vinohrady, Dept Internal Med & Hematol, Prague, Czech Republic

[12] Colorado Blood Canc Inst, Denver, CO USA

[13] Sarah Cannon Res Inst, Denver, CO USA

[14] Med Univ Lodz, Dept Hematol, Lodz, Poland

[15] Copernicus Mem Hosp, Lodz, Poland

[16] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA

[17] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[18] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-163092

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：9995 / 9997

页数：3

共 50 条

[41] Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).
Chari, Ajai
Usmani, Saad Zafar
Mateos, Maria-Victoria
Van De Donk, Niels
Kaufman, Jonathan L.
Moreau, Philippe
Rocafiguera, Albert Oriol
Plesner, Torben
Benboubker, Lotfi
Liu, Kevin
Hellemans, Peter
Masterson, Tara J.
Clemens, Pamela L.
Farnsworth, Andrew
Nahi, Hareth
San-Miguel, Jesus
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[42] Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.
Rodriguez-Otero, Paula
Mateos, Maria-Victoria
Oriol, Albert
Larocca, Alessandra
Blade, Joan
Cavo, Michele
Leleu, Xavier
Nadeem, Omar
Hiemenz, John W.
Hassoun, Hani
Touzeau, Cyrille
Alegre, Adrian
Paner, Agne
Maisel, Christopher
Mazumder, Amitabha
Raptis, Anastasios
Thuresson, Marcus
Harmenberg, Johan
Harlin, Olof
Richardson, Paul G.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[43] Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study
Plesner, Torben
Arkenau, Hendrik-Tobias
Gay, Francesca Marianatal
Minnema, Monique C.
Boccadoro, Mario
Moreau, Philippe
Cavenagh, James D.
Perrot, Aurore
Laubach, Jacob
Ahmadi, Tahamtan
de Boer, Carla
Chen, Diana
Chiu, Christopher
Schecter, Jordan
Richardson, Paul G.
BLOOD, 2017, 130
[44] Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux
Usmani, Saad Z.
Dimopoulos, Meletios A.
Belch, Andrew
White, Darrell
Benboubker, Lofti
Cook, Gordon
Leiba, Merav
Morton, James
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Khokhar, Nushmia Z.
Guckert, Mary
Wu, Kaida
Qin, Xiang
Casneuf, Tineke
Chiu, Christopher
Sasser, A. Kate
San-Miguel, Jesus
BLOOD, 2016, 128 (22)
[45] Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: final results of the Phase 2 study DARIA
Terpos, Evangelos
Ntanasis-Stathopoulos, Ioannis
Gavriatopoulou, Maria
Katodritou, Eirini
Hatjiharissi, Evdoxia
Malandrakis, Panagiotis
Verrou, Evgenia
Leonidakis, Alexandros
Migkou, Magdalini
Delimpasi, Sosana
Symeonidis, Argiris
Kastritis, Efstathios
Dimopoulos, Meletios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S213 - S214
[46] Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study
Plesner, Torben
Arkenau, Hendrik-Tobias
Gay, Francesca
Minnema, Monique C.
Boccadoro, Mario
Moreau, Philippe
Cavenagh, Jamie
Perrot, Aurore
Laubach, Jacob P.
Krejcik, Jakub
Ahmadi, Tahamtan
de Boer, Carla
Chen, Diana
Chiu, Christopher
Schecter, Jordan M.
Richardson, Paul G.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (03) : E35 - E39
[47] AN ONGOING OPEN-LABEL PHASE 1/2A STUDY OF THE SAFETY AND EFFICACY OF MELFLUFEN AND DEXAMETHASONE COMBINATION FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM)
Mellqvist, U. H.
Paba-Prada, C.
Palumbo, A.
Plesner, T.
Sonneveld, P.
Voorhees, P.
Byrne, C.
Harmenberg, J.
Nordstrom, E.
Richardson, P. G.
HAEMATOLOGICA, 2014, 99 : 375 - 376
[48] The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice
Leleu, Xavier
Boccadoro, Mario
Lee, Hans C.
Zonder, Jeffrey A.
Macro, Magaret
Ramasamy, Karthik
Hulin, Cyrille
Silar, Jiri
Kuhn, Matyas
Ren, Kaili
Bent-Ennakhil, Nawal
Bouillie, Sylvie
Cherepanov, Dasha
Stull, Dawn Marie
Terpos, Evangelos
BLOOD, 2021, 138
[49] Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA
Terpos, Evangelos
Ntanasis-Stathopoulos, Ioannis
Gavriatopoulou, Maria
Katodritou, Eirini
Hatjiharissi, Evdoxia
Malandrakis, Panagiotis
Verrou, Evgenia
Golfinopoulos, Stavros
Migkou, Magdalini
Manousou, Kyriaki
Delimpasi, Sosana
Symeonidis, Argiris
Kastritis, Efstathios
Dimopoulos, Meletios A.
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (03) : 396 - 407
[50] Oprozomib, Pomalidomide, and Dexamethasone (OPomd) in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): Initial Results of a Phase 1 b Study (NCT01999335)
Shah, Jatin
Niesvizky, Ruben
Stadtmauer, Edward
Rifkin, Robert M.
Berenson, James
Berdeja, Jesus G.
Sharman, Jeff P.
Lyons, Roger
Klippel, Zandra
Wong, Hansen
Chang, Yu-Lin
Usmani, Saad
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →